Specialty Pharmacy Acquisition Financing

The Transaction Behind the Search

The useful question behind specialty pharmacy acquisition financing is not whether debt exists in theory. It is which lender can underwrite the exact asset, cash flow and execution risk within the required timetable.

The financing has to support the purchase price without leaving the combined business overleveraged on day one. Pro forma leverage, integration liquidity and any seller rollover should be visible before lender distribution. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

The mandate should state exactly what is being financed and why the proposed debt is appropriate. In this vertical, the use of proceeds is typically acquisition, consolidation, equipment or growth capital in a regulated healthcare operating business. A lender should be able to trace every dollar of requested debt into a defined asset, acquisition, capex item or working-capital requirement. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

How the Deal Is Sized

For specialty pharmacy acquisition financing, lenders begin with repayment and recovery. Lenders focus on payer mix, reimbursement durability, clinician retention, site-level profitability and regulatory standing before giving full value to adjusted ebitda.

• Payer Mix And Receivables Aging should be supported by data that can be independently reconciled.
• Site-Level Financial Statements should be supported by data that can be independently reconciled.
• Provider Roster And Compensation Model should be supported by data that can be independently reconciled.
• Licenses And Compliance History should be supported by data that can be independently reconciled.
• Purchase Agreement Or Transaction Sources And Uses should be supported by data that can be independently reconciled.

Management should expect lenders to recalculate adjusted EBITDA, remove unsupported add-backs and test liquidity after closing. The usable debt amount is the number that still works after those adjustments. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

Debt Routes for This Mandate

The structure should match the risk that actually exists in specialty pharmacy acquisition financing. Relevant routes can include:

• Revolving Working-Capital Capacity when the lender has the required collateral, cash-flow or priority support.
• Seller Paper Or Junior Capital Where Acquisition Leverage Needs Another Layer when the lender has the required collateral, cash-flow or priority support.
• Senior Secured Term Debt when the lender has the required collateral, cash-flow or priority support.
• Unitranche Private Credit when the lender has the required collateral, cash-flow or priority support.
• Equipment Finance Where Tangible Medical Assets Are Meaningful when the lender has the required collateral, cash-flow or priority support.

A blended capital stack can be more executable than forcing the full requirement into senior debt. The residual gap may be filled with seller paper, preferred capital, sponsor equity or a junior tranche where economics permit. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

Execution Risks to Resolve Early

• Recoupment And Billing Exposure can change leverage, pricing or the lender universe if it is not addressed before underwriting.
• Provider Or Physician Retention can change leverage, pricing or the lender universe if it is not addressed before underwriting.
• Licensing And Compliance can change leverage, pricing or the lender universe if it is not addressed before underwriting.
• Integration Risk After Closing can change leverage, pricing or the lender universe if it is not addressed before underwriting.
• Reimbursement Concentration can change leverage, pricing or the lender universe if it is not addressed before underwriting.

The purpose of structuring is to assign these risks rather than describe them vaguely. Reserves, covenants, insurance, cash control, completion support and additional equity should each solve a named downside scenario. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

Documents a Credit Team Will Expect

• provider roster and compensation model
• licenses and compliance history
• purchase agreement or transaction sources and uses
• equipment schedule where applicable
• payer mix and receivables aging
• site-level financial statements

For specialty pharmacy acquisition financing, the first lender memorandum should also show current debt, requested proceeds, sources and uses, proposed maturity, security, expected closing date and the exact repayment path. The objective is to let a credit professional screen the mandate without reconstructing the transaction from raw files.

How to Take Specialty Pharmacy Acquisition Financing to the Debt Market

1. Confirm eligibility, use of proceeds and the legal borrower.
2. Size debt under a base case and a downside case.
3. Prepare lender materials and the initial diligence file.
4. Map banks, private-credit funds and specialty lenders by mandate fit.
5. Run controlled outreach and management Q&A.
6. Compare term sheets on proceeds, covenants, economics and execution risk.
7. Coordinate diligence, documentation and closing conditions through funding.

FAQ About Specialty Pharmacy Acquisition Financing

Which lenders can finance specialty pharmacy acquisition financing?

The realistic lender set can include private-credit funds, banks, specialty finance companies and asset-based lenders depending on the structure. The selection should follow the transaction's reimbursement concentration and recoupment and billing exposure exposure rather than a generic lender list. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

How much can be borrowed for specialty pharmacy acquisition financing?

Debt proceeds are constrained by the weakest underwriting test, which may be cash-flow coverage, collateral value, leverage, project DSCR or lender policy. The requested amount should be supported by a downside case, not only management's target. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

What information is required before approaching lenders?

The opening file should include payer mix and receivables aging, site-level financial statements and provider roster and compensation model, together with current financials, ownership, debt and a precise use of proceeds. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.

Does Financely provide the capital directly?

Financely acts as a paid debt advisor, broker and arranger. The selected bank, fund or specialty lender makes the independent credit decision and provides the capital. For specialty pharmacy acquisition financing, this issue should be tested against the actual debt package rather than assumed from a different transaction.